Arecor Therapeutics PLC Exercise of rollover options & Total Voting Rights (2947C)
June 09 2023 - 10:35AM
UK Regulatory
TIDMAREC
RNS Number : 2947C
Arecor Therapeutics PLC
09 June 2023
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Exercise of rollover options and Total Voting Rights
Cambridge, UK, 9 June 2023: Arecor Therapeutics plc (AIM: AREC),
the biopharmaceutical company advancing today's therapies to enable
healthier lives, announces that it has issued and allotted 7,471
new Ordinary Shares of 1 pence each in the share capital of the
Company following an exercise of options on 8 June 2023 at an
exercise price of 1 pence per Ordinary Share. The options exercised
were part of the rollover of share options previously granted under
the Arecor Limited EMI Share Option Plan 2018 ("Option Rollover").
Details of the Option Rollover are set out in the Company's
Admission Document.
Admission
Following the above transactions, application has been made for
the 7,471 new Ordinary Shares to be admitted to trading on AIM
("Admission") and dealings are expected to commence on, or around,
14 June 2023. The new Ordinary Shares will rank pari passu with the
Company's existing Ordinary Shares.
The total number of Ordinary Shares in issue following Admission
will be 30,625,654. Accordingly, the figure of 30,625,654 may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the
FCA's Disclosure and Transparency Rules.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner, David Daley, Lindsey Email: arecor@consilium-comms.com
Neville
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary technology platform,
Arestat(TM), we are developing an internal portfolio of proprietary
products in diabetes and other indications, as well as working with
leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat(TM) platform is supported by an
extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRFLMITMTJMBIJ
(END) Dow Jones Newswires
June 09, 2023 10:35 ET (14:35 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Sep 2023 to Sep 2024